Literature DB >> 23378057

Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia.

Susan M Cleveland1, Stephen Smith, Rati Tripathi, Elizabeth M Mathias, Charnise Goodings, Natalina Elliott, Dunfa Peng, Wael El-Rifai, Dajun Yi, Xi Chen, Liqi Li, Charles Mullighan, James R Downing, Paul Love, Utpal P Davé.   

Abstract

LIM domain only 2 (Lmo2) is frequently deregulated in sporadic and gene therapy-induced acute T-cell lymphoblastic leukemia (T-ALL) where its overexpression is an important initiating mutational event. In transgenic and retroviral mouse models, Lmo2 expression can be enforced in multiple hematopoietic lineages but leukemia only arises from T cells. These data suggest that Lmo2 confers clonal growth advantage in T-cell progenitors. We analyzed proliferation, differentiation, and cell death in CD2-Lmo2 transgenic thymic progenitor cells to understand the cellular effects of enforced Lmo2 expression. Most impressively, Lmo2 transgenic T-cell progenitor cells were blocked in differentiation, quiescent, and immortalized in vitro on OP9-DL1 stromal cells. These cellular effects were concordant with a transcriptional signature in Lmo2 transgenic T-cell progenitor cells that is also present in hematopoietic stem cells (HSCs) and early T-cell precursor ALL. These results are significant in light of the crucial role of Lmo2 in the maintenance of the HSC. The cellular effects and transcriptional effects have implications for LMO2-dependent leukemogenesis and the treatment of LMO2-induced T-ALL.
Copyright © 2013 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378057      PMCID: PMC3652616          DOI: 10.1002/stem.1345

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  50 in total

1.  Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro.

Authors:  Thomas M Schmitt; Juan Carlos Zúñiga-Pflücker
Journal:  Immunity       Date:  2002-12       Impact factor: 31.745

2.  Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Sabine Herblot; Teresa Palomero; Mark Hansen; Trang Hoang; Edward A Fox; A Thomas Look
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

3.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

4.  Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice.

Authors:  G A Neale; J E Rehg; R M Goorha
Journal:  Leukemia       Date:  1997-04       Impact factor: 11.528

5.  The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development.

Authors:  A J Warren; W H Colledge; M B Carlton; M J Evans; A J Smith; T H Rabbitts
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

6.  TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB.

Authors:  Jennifer O'Neil; Jennifer Shank; Nicole Cusson; Cornelis Murre; Michelle Kelliher
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

8.  T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes.

Authors:  P Fisch; T Boehm; I Lavenir; T Larson; J Arno; A Forster; T H Rabbitts
Journal:  Oncogene       Date:  1992-12       Impact factor: 9.867

9.  Differential effects of zeta and eta transgenes on early alpha/beta T cell development.

Authors:  P E Love; E W Shores; E J Lee; A Grinberg; T I Munitz; H Westphal; A Singer
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

10.  Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia.

Authors:  I Wadman; J Li; R O Bash; A Forster; H Osada; T H Rabbitts; R Baer
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

View more
  27 in total

1.  PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.

Authors:  Evgeni Efimenko; Utpal P Davé; Irina V Lebedeva; Yao Shen; Maria J Sanchez-Quintero; Daniel Diolaiti; Andrew Kung; Brian J Lannutti; Jianchung Chen; Ronald Realubit; Zoya Niatsetskaya; Vadim Ten; Charles Karan; Xi Chen; Andrea Califano; Thomas G Diacovo
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

Review 2.  Developmental gene networks: a triathlon on the course to T cell identity.

Authors:  Mary A Yui; Ellen V Rothenberg
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

3.  Transcriptome profiling reveals signaling conditions dictating human spermatogonia fate in vitro.

Authors:  Kun Tan; Hye-Won Song; Merlin Thompson; Sarah Munyoki; Meena Sukhwani; Tung-Chin Hsieh; Kyle E Orwig; Miles F Wilkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-13       Impact factor: 11.205

4.  LMO2 induces T-cell leukemia with epigenetic deregulation of CD4.

Authors:  Susan M Cleveland; Charnise Goodings; Rati M Tripathi; Natalina Elliott; Mary Ann Thompson; Yan Guo; Yu Shyr; Utpal P Davé
Journal:  Exp Hematol       Date:  2014-05-02       Impact factor: 3.084

5.  High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.

Authors:  Bastien Gerby; Diogo F T Veiga; Jana Krosl; Sami Nourreddine; Julianne Ouellette; André Haman; Geneviève Lavoie; Iman Fares; Mathieu Tremblay; Véronique Litalien; Elizabeth Ottoni; Milena Kosic; Dominique Geoffrion; Joël Ryan; Paul S Maddox; Jalila Chagraoui; Anne Marinier; Josée Hébert; Guy Sauvageau; Benjamin H Kwok; Philippe P Roux; Trang Hoang
Journal:  J Clin Invest       Date:  2016-10-31       Impact factor: 14.808

6.  Hhex is Required at Multiple Stages of Adult Hematopoietic Stem and Progenitor Cell Differentiation.

Authors:  Charnise Goodings; Elizabeth Smith; Elizabeth Mathias; Natalina Elliott; Susan M Cleveland; Rati M Tripathi; Justin H Layer; Xi Chen; Yan Guo; Yu Shyr; Rizwan Hamid; Yang Du; Utpal P Davé
Journal:  Stem Cells       Date:  2015-05-27       Impact factor: 6.277

7.  Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.

Authors:  Charnise Goodings; Rati Tripathi; Susan M Cleveland; Natalina Elliott; Yan Guo; Yu Shyr; Utpal P Davé
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

8.  Fli-1 regulates the DN2 to DN3 thymocyte transition and promotes γδ T-cell commitment by enhancing TCR signal strength.

Authors:  Monique F M A Smeets; David L Wiest; David J Izon
Journal:  Eur J Immunol       Date:  2014-07-24       Impact factor: 5.532

9.  LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.

Authors:  Justin H Layer; Catherine E Alford; W Hayes McDonald; Utpal P Davé
Journal:  Mol Cell Biol       Date:  2015-11-23       Impact factor: 4.272

10.  Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.

Authors:  LiQi Li; Apratim Mitra; Kairong Cui; Bin Zhao; Seeyoung Choi; Jan Y Lee; Daniel B Stamos; Dalal El-Khoury; Claude Warzecha; Karl Pfeifer; Joyce Hardwick; Keji Zhao; Bryan Venters; Utpal P Davé; Paul E Love
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.